Xinli Pang

517 total citations
17 papers, 137 citations indexed

About

Xinli Pang is a scholar working on Immunology, Surgery and Physiology. According to data from OpenAlex, Xinli Pang has authored 17 papers receiving a total of 137 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 6 papers in Surgery and 4 papers in Physiology. Recurrent topics in Xinli Pang's work include Phagocytosis and Immune Regulation (10 papers), Immune cells in cancer (5 papers) and Pancreatic function and diabetes (5 papers). Xinli Pang is often cited by papers focused on Phagocytosis and Immune Regulation (10 papers), Immune cells in cancer (5 papers) and Pancreatic function and diabetes (5 papers). Xinli Pang collaborates with scholars based in China, Canada and United States. Xinli Pang's co-authors include Robert A. Uger, Penka S. Petrova, Natasja Nielsen Viller, Mark Wong, Karen Dodge, Gloria H. Y. Lin, Emma Linderoth, Lisa D. Johnson, Adam H. Hart and Masanori Hirashima and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and PLoS ONE.

In The Last Decade

Xinli Pang

16 papers receiving 131 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xinli Pang China 6 62 31 29 29 25 17 137
Verena Barocke Germany 3 72 1.2× 48 1.5× 38 1.3× 46 1.6× 6 0.2× 3 147
Roger K. Henry United States 8 69 1.1× 10 0.3× 100 3.4× 26 0.9× 19 0.8× 19 221
Christian Reimann Germany 5 45 0.7× 114 3.7× 81 2.8× 59 2.0× 30 1.2× 7 220
Thomas Balligand Belgium 6 19 0.3× 45 1.5× 70 2.4× 17 0.6× 13 0.5× 12 146
Katarzyna Anna Baranowska Norway 6 19 0.3× 75 2.4× 120 4.1× 39 1.3× 6 0.2× 11 176
Juliana Vélez United States 5 16 0.3× 30 1.0× 72 2.5× 38 1.3× 8 0.3× 8 119
K R Reynolds United States 5 12 0.2× 104 3.4× 66 2.3× 11 0.4× 24 1.0× 10 190
О. В. Головенко Russia 2 31 0.5× 8 0.3× 85 2.9× 40 1.4× 21 0.8× 4 169
Clémence Virely United Kingdom 4 55 0.9× 9 0.3× 68 2.3× 23 0.8× 27 1.1× 7 133
Ayako Matsuki Japan 6 146 2.4× 5 0.2× 31 1.1× 24 0.8× 45 1.8× 6 210

Countries citing papers authored by Xinli Pang

Since Specialization
Citations

This map shows the geographic impact of Xinli Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinli Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinli Pang more than expected).

Fields of papers citing papers by Xinli Pang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinli Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinli Pang. The network helps show where Xinli Pang may publish in the future.

Co-authorship network of co-authors of Xinli Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Xinli Pang. A scholar is included among the top collaborators of Xinli Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinli Pang. Xinli Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Krishnamoorthy, Mithunah, Natasja Nielsen Viller, Mark Wong, et al.. (2023). The CD47-Blocking Immune Checkpoint Inhibitor Maplirpacept Does Not Interfere with Blood Transfusion Compatibility Testing. Blood. 142(Supplement 1). 4037–4037.
3.
4.
Xu, Cong, Tangzhiming Li, Jie Yuan, et al.. (2022). Iron metabolism-related genes reveal predictive value of acute coronary syndrome. Frontiers in Pharmacology. 13. 1040845–1040845. 4 indexed citations
5.
Ou, Z. W., Zaixin Yu, Lin Zhao, et al.. (2022). Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients. Frontiers in Cardiovascular Medicine. 9. 939791–939791. 6 indexed citations
6.
Viller, Natasja Nielsen, et al.. (2018). Abstract 2720: The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis. Cancer Research. 78(13_Supplement). 2720–2720. 1 indexed citations
7.
Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2017). TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 12(10). e0187262–e0187262. 51 indexed citations
8.
Lin, Gloria H. Y., Hui Chen, Mark Wong, et al.. (2017). Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model. Cancer Research. 77(13_Supplement). 2646–2646. 1 indexed citations
9.
Linderoth, Emma, Vivian Lee, Mark Wong, et al.. (2017). Abstract 2653: The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor. Cancer Research. 77(13_Supplement). 2653–2653. 5 indexed citations
10.
Lin, Gloria H. Y., Vivian Lee, Karen Dodge, et al.. (2016). Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages. Cancer Research. 76(14_Supplement). 2345–2345. 1 indexed citations
11.
Viller, Natasja Nielsen, Emma Linderoth, Lisa D. Johnson, et al.. (2016). Abstract B028: Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8+ T cell responses in vitro. Cancer Immunology Research. 4(11_Supplement). B028–B028. 1 indexed citations
12.
Petrova, Penka S., et al.. (2015). Abstract 4271: Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic. Cancer Research. 75(15_Supplement). 4271–4271. 1 indexed citations
13.
Uger, Robert A., Karen Dodge, Xinli Pang, & Penka S. Petrova. (2014). Abstract 5011: Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding. Cancer Research. 74(19_Supplement). 5011–5011. 2 indexed citations
14.
Zeng, Aiguo, Xinli Pang, Na Wu, et al.. (2014). Solubility of daidzein in propylene glycol plus water cosolvent mixtures. Fluid Phase Equilibria. 366. 127–133. 9 indexed citations
15.
Uger, Robert A., Xinli Pang, Mark Wong, et al.. (2013). Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability. Blood. 122(21). 3935–3935. 3 indexed citations
16.
He, Xiaohui, Yanwen Bi, Wenjie Yue, et al.. (2008). The Proteasome Inhibitor Bortezomib Inhibits Intimal Hyperplasia of Autologous Vein Grafting in Rat Model. Transplantation Proceedings. 40(5). 1722–1726. 4 indexed citations
17.
Kimura, Yuki, Adam H. Hart, Masanori Hirashima, et al.. (2002). Zinc Finger Protein, Hzf, Is Required for Megakaryocyte Development and Hemostasis. The Journal of Experimental Medicine. 195(7). 941–952. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena Barocke Breakdown of academic impact, for papers by Roger K. Henry Breakdown of academic impact, for papers by Christian Reimann Breakdown of academic impact, for papers by Thomas Balligand Breakdown of academic impact, for papers by Katarzyna Anna Baranowska Breakdown of academic impact, for papers by Juliana Vélez Breakdown of academic impact, for papers by K R Reynolds Breakdown of academic impact, for papers by О. В. Головенко Breakdown of academic impact, for papers by Clémence Virely Breakdown of academic impact, for papers by Ayako Matsuki
Rankless by CCL
2026